Alemtuzumab FDA Link

An anti-CD52 ANTIGEN monoclonal antibody used for the treatment of certain types of CD52-positive lymphomas (e.g., CHRONIC LYMPHOCYTIC LEUKEMIA; CUTANEOUS T-CELL LYMPHOMA; and T-CELL LYMPHOMA). Its mode of actions include ANTIBODY-DEPENDENT CELL CYTOTOXICITY.

Also Known As:

Campath; Campath 1H; Campath 1G; Campath 1M; Campath-1-G; Campath-1G; Campath-1H; Campath-1M; Lemtrada; MabCambath; Monoclonal Antibody Campath-1H; Antibody Campath-1H, Monoclonal; Campath 1 G; Campath-1H, Monoclonal Antibody; Campath1G; Campath1H; Monoclonal Antibody Campath 1H

Amino Acids, Peptides, and Proteins: 1
- Proteins: 496323
  - Blood Proteins: 12679
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Alemtuzumab: 1784
    - Immunoproteins: 43
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Alemtuzumab: 1784
  - Globulins: 3119
    - Serum Globulins: 555
      - Immunoglobulins: 30911
        Antibodies: 135587
        Monoclonal Antibodies: 57170
        Humanized Monoclonal Antibodies: 220
        Alemtuzumab: 1784

K E Towlson Selected Research

K E Towlson Research Topics

Disease

Drug/Important Bio-Agent (IBA)